BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell
Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.